Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral first-line therapy for acromegaly patients inadequately served by surgery or ineligible for it. This approval introduces a daily pill alternative competing against injectable blockbuster drugs from Novartis and Ipsen. Clinical trials confirmed substantial reduction in growth hormone levels with a favorable safety profile. CEO Scott Struthers highlighted the milestone as transformative both for patients and the company.